Chur

Researchers are investigating new treatments for advanced ovarian cancer, specifically in patients who do not have homologous recombination deficiency (non-HRD positive). This Phase 3 study aims to assess whether maintenance treatment with sacituzumab tirumotecan (sac-TMT), alone or combined with bevacizumab, can improve progression-free survival compared to the current standard care after initial platinum-based chemotherapy and surgery. Participants receive sacituzumab tirumotecan through intravenous infusion at a dose of 4 mg/kg. Some also receive bevacizumab intravenously at 15 mg/kg as part of their maintenance treatment. Before sac-TMT infusion, participants are given prophylactic steroid mouthwash and recommended rescue medications including histamine-1 and histamine-2 receptor antagonists, acetaminophen or equivalent, and dexamethasone or equivalent. The study compares these treatments to standard care or observation following first-line chemotherapy. During the study, participants are monitored for progression-free survival for up to approximately 49 months. Researchers will assess how long participants live without their cancer getting worse. Throughout the trial, safety and response to treatment are evaluated. The study includes women aged 18 years and older who have completed surgery and first-line chemotherapy with specific responses and meet certain health criteria.

Researchers are evaluating treatments for people with extensive stage small-cell lung cancer (ES-SCLC). This phase 3 study compares the effectiveness of adding tarlatamab to a combination of durvalumab, carboplatin, and etoposide against the combination without tarlatamab. The main goal is to see which treatment better prolongs overall survival and progression-free survival over about 3.5 years. Participants receive intravenous infusions of the study drugs. One group gets tarlatamab combined with durvalumab, carboplatin, and etoposide, while the other group receives durvalumab, carboplatin, and etoposide alone. All treatments are given as first-line therapy for their lung cancer. During the study, participants will be monitored regularly to assess their response to treatment and overall health. Researchers will measure overall survival and progression-free survival to evaluate treatment benefit. The study also involves ongoing safety monitoring, and participants will be followed for up to approximately 3.5 years to collect these outcomes.

Researchers are evaluating the safety and effectiveness of divarasib combined with pembrolizumab compared to pembrolizumab with pemetrexed and either carboplatin or cisplatin. The study focuses on adults with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) that has a specific KRAS G12C mutation. This is a Phase III trial aiming to improve first-line treatment options for these patients. Participants will receive one of two treatment combinations. One group will take divarasib orally once daily along with pembrolizumab given through an intravenous infusion every three weeks. The other group will receive pembrolizumab with pemetrexed and either carboplatin or cisplatin, all administered by intravenous infusion every three weeks. Treatment schedules and dosages are carefully monitored during the study. Throughout the study, participants will be regularly assessed for progression-free survival and overall survival, with follow-up lasting up to approximately five years. Researchers will perform various evaluations including tumor measurements and safety monitoring. This long-term observation helps to understand the treatments' effects and safety over time, supporting informed decisions for future lung cancer therapies.

Researchers are evaluating the safety and effectiveness of INCB123667 in women with platinum-resistant ovarian cancer that shows overexpression of Cyclin E1. This phase 2 study focuses on participants with high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have developed resistance to platinum-based therapies. The trial aims to assess how well the drug works and its safety profile in this specific patient group. Participants will receive INCB123667 orally twice a day. The study includes women who have undergone between one and four prior systemic therapies after their initial diagnosis and have platinum-resistant disease. A pretreatment biopsy is required, preferably a fresh sample but an archival tissue sample not older than five years is also acceptable. The study monitors the participants over time to evaluate their response to the treatment. During the study, researchers will closely observe participants through assessments that include biopsies and monitoring for safety and response to treatment over a period of up to two years. The main outcome measure is the objective response evaluated by an independent review committee. Safety and efficacy data will guide the understanding of INCB123667's potential for treating this challenging form of ovarian cancer.

Researchers are evaluating the effectiveness, safety, and patient-reported outcomes of standard treatments for people with relapsed or refractory multiple myeloma in real-world clinical settings. This study follows participants over 24 months to observe how current standard care works for those who have previously received treatment for this condition. The research includes participants who meet specific diagnostic criteria and have measurable disease based on recognized myeloma guidelines. The study does not involve any experimental treatment; instead, it observes patients receiving standard care as decided by their doctors. Participants include those who have undergone multiple prior therapies, including specific drug classes and targeted treatments, depending on the study period. The study covers different periods with slightly varied eligibility and treatment histories, including a group starting talquetamab treatment for relapsed or refractory multiple myeloma. Participants will be monitored for up to 52 months to evaluate their response to treatment, including overall response rates. Researchers will collect data on their health status, treatment history, and patient-reported outcomes. Safety and effectiveness will be assessed based on clinical evaluations and disease progression as determined by their healthcare providers throughout the study period.

Researchers are evaluating a drug called sigvotatug vedotin alone and in combination with pembrolizumab, with or without chemotherapy, to determine its safety and effects in people with various advanced solid tumors. This Phase 1 study includes participants with specific cancers like non-small cell lung cancer, head and neck squamous cell cancer, HER2-negative breast cancer, esophageal cancers, ovarian cancer, and others. The trial aims to find out the side effects of sigvotatug vedotin and whether it can treat these solid tumors effectively. The study is divided into four parts. Part A focuses on finding the right dose of sigvotatug vedotin. Part B tests the safety and effectiveness of that dose. Parts C and D look at the safety and effectiveness of sigvotatug vedotin combined with pembrolizumab alone or with chemotherapy drugs carboplatin or cisplatin. Participants receive these drugs intravenously, with pembrolizumab given every 3 or 6 weeks and chemotherapy every 3 weeks depending on the drug. During the study, participants undergo tumor biopsies, physical exams, and disease assessments to monitor treatment effects. Researchers track side effects, lab abnormalities, and dose-limiting toxicities for up to 30-37 days after the last dose of sigvotatug vedotin, and for up to 3 years after pembrolizumab treatment. The study follows participants with regular safety monitoring and evaluations of tumor response throughout the trial.

Researchers are evaluating whether adding sacituzumab tirumotecan to pembrolizumab after surgery improves treatment outcomes for adults with resectable non-small cell lung cancer (NSCLC) who have not achieved a complete response after initial therapy. This Phase 3 study compares the combination of sacituzumab tirumotecan and pembrolizumab to pembrolizumab alone, focusing on disease-free survival as measured by a blinded independent central review. Participants receive neoadjuvant treatments including pembrolizumab with platinum-based doublet chemotherapy (such as cisplatin, pemetrexed, gemcitabine, carboplatin, or paclitaxel) before surgery. After surgery, those without a complete pathological response are randomized to receive either sacituzumab tirumotecan every two weeks for up to 24 weeks plus pembrolizumab every six weeks for up to 42 weeks, or pembrolizumab alone. Rescue medications may be given to prevent infusion reactions and oral side effects. During the study, participants undergo regular radiological assessments and provide tumor tissue samples to evaluate markers like PD-L1 and TROP2. Researchers monitor disease-free survival for up to approximately 93 months. Safety assessments, recovery from previous therapies, and control of infections such as HIV or hepatitis are also part of participant evaluations throughout the study period.

Researchers are evaluating the safety and effectiveness of a new combination treatment using BMS-986489 (a fixed dose combination of BMS-986012 and Nivolumab) alongside Carboplatin and Etoposide compared to the current standard treatment with Atezolizumab plus Carboplatin and Etoposide. This study focuses on adults with extensive-stage small cell lung cancer and is conducted as a phase 3 randomized, double-blind, multicenter trial. The goal is to find out which combination works better as a first-line therapy for this advanced lung cancer. Participants will receive either BMS-986489 combined with Carboplatin and Etoposide or Atezolizumab combined with Carboplatin and Etoposide. Each drug will be given at specified doses on certain days according to the study protocol. The study compares these two treatment approaches to see their effects and safety when used as initial therapy for extensive-stage small cell lung cancer. During the study, participants will be closely monitored over a period of up to 5 years to assess overall survival. Researchers will use imaging techniques like CT scans or MRIs to measure tumor response and will evaluate participants' health and ability to perform normal activities. Safety and side effects will also be tracked throughout the study to ensure participant well-being.

Researchers are investigating the safety and effectiveness of several new treatments, with or without pembrolizumab and chemotherapy, for adults with advanced esophageal squamous cell carcinoma who have previously received PD-1/PD-L1 based therapies. This Phase 1/2 multicenter, randomized, open-label study focuses on participants whose cancer has progressed after one prior standard treatment including a platinum agent and PD-1/PD-L1 immune therapy. The study aims to better understand how these investigational agents perform in this specific patient group. Participants may receive different combinations of treatments including intravenous infusions of pembrolizumab, MK-4830, paclitaxel, irinotecan, and sacituzumab tirumotecan, as well as oral lenvatinib daily. The dosages and schedules vary, for example, paclitaxel is given on days 1, 8, and 15 every 28 days, while irinotecan is administered every 14 days. Supportive care and medications such as antihistamines, corticosteroids, and acetaminophen are allowed to manage side effects. Some arms of the study involving pembrolizumab plus MK-4830 with paclitaxel/irinotecan or lenvatinib are no longer enrolling. During the study, participants will be monitored for adverse events and dose-limiting toxicities, especially during an initial safety lead-in phase of about three weeks. Researchers will also track treatment discontinuation due to side effects and measure the tumor response over up to 48 months. Assessments include clinical evaluations, imaging, and tissue sample analyses. The study is designed to gather detailed safety and efficacy data to inform future treatment options for esophageal cancer patients.

Researchers are evaluating the safety, tolerability, and effectiveness of Pumitamig alone or combined with Ipilimumab or Cabozantinib in adults with advanced Renal Cell Carcinoma (RCC). This phase 1/2 study includes participants with locally advanced or metastatic RCC, including clear cell and non-clear cell types, to better understand treatment options for this condition. The trial aims to assess both side effects and tumor response over an extended period. Participants receive specified doses of Pumitamig alone or in combination with Ipilimumab or Cabozantinib on scheduled days during the study. Nivolumab is also involved as part of the treatment regimen. The study is open-label, randomized, and multi-center, allowing comparison of these treatment approaches over time. The dosing schedules and combinations are carefully monitored throughout the trial. During the study, participants undergo evaluations for adverse events, including serious side effects, dose-limiting toxicities, and events leading to discontinuation or death, monitored up to about two years after treatment ends. Researchers also measure tumor responses using established criteria (RECIST v1.1). Safety and treatment effects are tracked closely to provide comprehensive data on these therapies for advanced RCC.